Just weeks after Sun Pharma’s stock was hit by whistleblower allegations of insider trading, a second complaint reportedly filed to Indian regulators sent the drugmaker’s shares tumbling to a new six-year low.
Just weeks after Sun Pharma’s stock was hit by whistleblower allegations of insider trading, a second complaint reportedly filed to Indian regulators sent the drugmaker’s shares tumbling to a new six-year low.